Nordazepam Property

Melting point:

208-210°C

Boiling point:

453.1±45.0 °C(Predicted)

Density 

1.2576 (rough estimate)

refractive index 

1.6330 (estimate)

Flash point:

11 °C

storage temp. 

2-8°C

solubility 

DMSO: >10mg/mL

pka

pKa 3.5 12.0 (5%MeOH in H2O t=20 I=0.15) (Uncertain)

form 

neat &_& powder

color 

white to light tan

LogP

2.930

NIST Chemistry Reference

Nordazepam(1088-11-5)

EPA Substance Registry System

2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-5-phenyl- (1088-11-5)

Safety

Hazard Codes 

Xn,T,F

Risk Statements 

22-39/23/24/25-23/24/25-11

Safety Statements 

7-16-36/37-45

RIDADR 

3249

WGK Germany 

3

RTECS 

DF1750000

HazardClass 

6.1(b)

PackingGroup 

III

HS Code 

2933910000

Toxicity

LD50 in mice (mg/kg): 2750 orally, >400 i.p. (Randall); LD50 in mice, rats (mg/kg): 1300, >5200 orally (company communication)

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P501Dispose of contents/container to..…

Nordazepam Chemical Properties,Usage,Production

Chemical Properties

Off-White Solid

Originator

Madar,Ravizza, Italy ,1973

Uses

The primary metabolite of Diazepam. A ligand for the GABAA receptor benzodiazepine modulatory site. Anxiolytic. Controlled substance (depressant).

Uses

The primary metabolite of diazepam. A ligand for the GABAA receptor benzodiazepine modulatory site. This is a controlled drug precursor therefore a liscence may be required for purchase

Definition

ChEBI: A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.

Manufacturing Process

A solution of 3.1 g of (2-benzoyl-4-chlorophenyl-carbamoylmethyl)carbamic acid benzyl ester in 30 cc of 20% hydrobromic acid in glacial acetic acid was stirred for 45 minutes at room temperature. On addition of 175 cc of anhydrous ether, a gummy solid precipitated. After several minutes the ether solution was decanted. The resultant 5-chloro-2-glycylaminobenzophenone was not isolated, but about 155 cc of ether was added to the residue and after chilling in an ice bath, 10% sodium hydroxide was added until the mixture was alkaline. The ether layer was then separated, washed twice with water and dried over sodium sulfate. After filtration, the ether solution was concentrated to dryness in vacuo. The residue was crystallized from benzene to yield 7-chloro-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one.

Therapeutic Function

Tranquilizer

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 25, p. 459, 1988 DOI: 10.1002/jhet.5570250220
The Journal of Organic Chemistry, 26, p. 4936, 1961 DOI: 10.1021/jo01070a038